Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pricing Debate

Set Alert for Pricing Debate

PhRMA Uses Allergan Stage In Campaign To Keep Focus On Industry's Reputation For Innovation

PhRMA CEO Stephen Ubl visited Allergan's Irvine, Calif. R&D and manufacturing campus as the trade association continues its "Go Boldly" campaign promoting biopharma innovation in an effort to counteract the hit the industry's reputation has taken from drug pricing concerns.

Innovation Pricing Debate Research and Development Strategies

Latest From Pricing Debate

Brand Exclusivity 'Gaming' To Be Addressed At US FDA Meeting

Commissioner Gottlieb outlines several steps agency is taking – including potentially dropping requirement for shared REMS – to create more competitive generic marketplace.

Generic Drugs Pricing Debate

HHS Action On Drug Pricing: Here's Who Secretary Price Is Listening To

HHS is expected to move ahead with action to address high drug prices following a series of stakeholder roundtables held over the past month.

Pricing Debate Pharmacy Benefit Management

Mehta Analysis: Biopharma's 10% Myth

Viren Mehta, founder of Mehta Partners, LLC, considers the oft-repeated statement that the cost of drugs represents only 10% of US healthcare expenditure. Does it matter that the figure excludes a large and growing segment of medicine spending?

United States Pricing Debate

Trump's Medicaid Funding Change Could Alter Drug Access, Rebates

Budget proposal to fund state Medicaid programs through per capita cap or block grant would save $610bn over 10 years, administration says; budget calls for clarifying treatment of value-based pricing and fostering exchange of pre-approval information between manufacturers and payers.

Pricing Debate Medicaid

Foreign Pharma Takes Simmering Price Concerns To New Korea Govt

Amid an escalating tussle with the health ministry over the level of South Korean drug prices, foreign pharma firms operating in the country are now proposing the launch of a new joint study on the issue with the incoming government.

South Korea Pricing Debate

Canada Plans Drug Price Reductions By Changing Reference Country List

Canadian authorities are consulting on potential new measures for curbing high drug prices. One of these would extend the list of countries it uses for international price comparisons.

Regulation BioPharmaceutical

Taking Big Pharma’s R&D Argument Literally: Cut Prices, Or Increase Spending?

Former Obama Administration official offers sophisticated and complicated approach to value-based pricing, tied back to drug development costs. The complexity alone makes the idea a non-starter for the current Administration, but it also begs the question of whether it would be more likely to cut costs – or just increase R&D spending?

Pricing Debate Medicare

Novo Nordisk CEO Puts Pricing On The Line

Lars Fruergaard Jørgensen, Novo Nordisk's CEO, says the group's pledge on price transparency, goals for improved outcomes and experimental use of digital health are commercially linked.

Commercial Companies

Gottlieb Places Drug Pricing Out Front In First Speech To US FDA Staff

New FDA Commissioner tells employees that 'too many consumers are priced out of medicines they need' and that FDA must take meaningful steps to get lower cost alternatives to market.

FDA Pricing Debate
See All
UsernamePublicRestriction

Register